Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics Previous close 739.40
Open 773.80
Day range —
52-week range 566.40 910.00
Off day high 0.00%
Off 52-week high −14.97%
Volume 9.00
Avg. volume (3M) 23.00
Market cap 48.66B
EPS (TTM) 22.49
Forward P/E —
P/E ratio (TTM) 34.41
Dividend yield —
Beta (5Y) —
Shares outstanding 62.89M
Short interest —
Earnings date Oct 22, 2026
Analyst target —
Profit margin —
No recent coverage in the 4Search index.
From articles in the 4Search news index.
Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs.
From Wikipedia , CC BY-SA 4.0
Earnings
Next report: Thu, Oct 22, 2026
Not eligible for Gainers, Losers, Most active (U.S. stocks worth $2 billion or more only).
Not eligible for Small-cap gainers, Aggressive small caps (U.S. stocks worth under $2 billion only).
Not eligible for Growth tech (U.S. technology stocks only).
Not eligible for Undervalued large caps (U.S. stocks worth $10 billion or more only).
A day counts when it ranked in the top 25 of a list. Tracked since Oct 10, 2026.
Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Conservative index. Terms of use .